Abbott Announces Crohn's Disease Trial to Explore Benefit of New Therapeutic Monitoring Parameters for Patients

ABBOTT PARK, Illinois, March 30, 2011 - Abbott (NYSE: ABT) announced today it enrolled the first patient in the
CALM Study, a clinical trial with HUMIRA(R) (adalimumab), to determine if
tailoring therapy to more stringent measures of disease activity in patients
with early moderate to severe Crohn's disease will improve mucosal healing.
The study will assess patients monitored with those stringent criteria over
56 weeks compared to patients monitored with less stringent and more commonly
used clinical disease management criteria. This international study is
enrolling now in Austria, Belgium, Canada, Czech Republic, France, Germany,
Italy, Netherlands, Spain, Sweden, Switzerland, and the UK with the goal to
research the response rates of approximately 240 people diagnosed with
Crohn's disease for less than four years who have had no more than one course
of corticosteroids and are naive to immunosuppressive and biologic therapy.

"We know Crohn's disease can be difficult to treat and that early
intervention may yield improved long-term outcomes," said Professor
Jean-Frederic Colombel, head of Gastroenterology, University of Lille,
France. "There are a number of objective measures by which we can quantify a
therapy's effect. Assessing these important objective measurement tools may
provide valuable information for physicians managing this disease."

The CALM study will evaluate tight control of disease activity, defined
as using stringent criteria based on the Crohn's disease activity index
(CDAI), high sensitivity C-reactive protein levels, the fecal Calprotectin
test and the need for continued corticosteroid use, versus disease management
based only on CDAI and corticosteroid use.

"The tight-control approach may offer a benchmark for drug therapies
relative to symptomatic treatment," said Eugene Sun, M.D., vice president,
Global Pharmaceutical Clinical Development, Abbott. "These important measures
may provide strides toward understanding and defining objective disease
management tools for Crohn's patients."

About the CALM Study

The CALM Study, an Open-Label, Multi-Center, Efficacy and Safety Study to
Evaluate Two Treatment Algorithms in Subjects with Moderate to Severe Crohn's
Disease, is a 56-week, multicenter, randomized, safety and efficacy trial of
prednisone, HUMIRA, and azathioprine using tight control versus clinically
driven management of Crohn's disease to evaluate mucosal healing in subjects
with moderately to severely active Crohn's disease, who are naive to
immunosuppressive and biologic therapy. Males and females ages 18 to 75 will
be enrolled at approximately 60 international study sites across Europe and
Canada. Eligible patients will have been diagnosed with Crohn's disease using
imaging technology or endoscopy not more than four years prior to enrolling.
They will have some degree of inflammation measured by high sensitivity
C-reactive protein level and fecal Calprotectin test. Additionally,
participants should not have any previous or current use of biologics for
Crohn's disease and should not have taken more than one previous course of a
corticosteroid.

About Crohn's Disease

Crohn's disease is a serious chronic inflammatory autoimmune disorder of
the gastrointestinal tract. It most commonly affects the end of the small
intestine or the ileum, however, it may involve any part of the
gastrointestinal tract. Symptoms can range from diarrhea, abdominal pain and
fever to rectal bleeding.

Important Treatment Considerations

Globally, prescribing information varies; refer to the individual country
product label for complete information.

HUMIRA is used to reduce the signs and symptoms of Crohn's disease (CD)
in adults who have not responded well to conventional treatments.

Serious infections, including sepsis, due to bacterial, mycobacterial,
invasive fungal, parasitic, or viral pathogens, rare cases of tuberculosis
(TB), and other opportunistic infections, including fatalities, have been
reported with the use of TNF-antagonists, including HUMIRA. Many of the
serious infections have occurred in patients on concomitant immunosuppressive
therapy that, in addition to their underlying disease could predispose them
to infections. Patients must be monitored closely for infections, including
tuberculosis, before, during and after treatment with HUMIRA. Treatment
should not be initiated in patients with active infections until infections
are controlled. In patients who have been exposed to tuberculosis and
patients who have travelled in areas of high risk of tuberculosis or endemic
mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis, the
risk and benefits of treatment with HUMIRA should be considered prior to
initiating therapy. HUMIRA should not be used by patients with active TB or
other severe infections such as sepsis and opportunistic infections. If
latent tuberculosis is diagnosed, appropriate treatment for latent
tuberculosis must be initiated with anti-tuberculosis prophylaxis therapy
before starting treatment with HUMIRA, and in accordance with local
recommendations. Patients who develop new infections while using HUMIRA
should be monitored closely and undergo a complete diagnostic evaluation.
HUMIRA should be discontinued if a patient develops a new serious infection
or sepsis, until the infection is controlled. Physicians should exercise
caution when considering use of HUMIRA in patients with a history of
recurring infection or with underlying conditions that may predispose
patients to infections.

TNF-blocking agents have been associated with reactivation of hepatitis B
(HBV) in patients who are chronic carriers of the virus. Some cases have been
fatal. Patients at risk for HBV infection should be evaluated for prior
evidence of HBV infection before initiating HUMIRA. Carriers of HBV who are
treated with HUMIRA should be closely monitored for active HBV infection
throughout therapy and for several months following termination of therapy.

TNF-antagonists, including HUMIRA, have been associated in rare cases
with demyelinating disease including multiple sclerosis. Serious allergic
reactions have been reported very rarely following HUMIRA administration.

More cases of malignancies including lymphoma have been observed among
patients receiving a TNF-antagonist compared with control patients in
clinical trials. However, the occurrence was rare. Furthermore, there is an
increased background lymphoma risk in rheumatoid arthritis patients with
long-standing, highly active, inflammatory disease, which complicates the
risk estimation. With the current knowledge, a possible risk for the
development of lymphomas or other malignancies in patients treated with a
TNF-antagonist cannot be excluded.

Rare postmarketing cases of hepatosplenic T-cell lymphoma, a disease with
a very aggressive and usually fatal outcome, have been identified in patients
treated with adalimumab. Some of these cases occurred in young adult patients
on concomitant treatment with azathioprine or 6-mercaptopurine used for
Crohn's disease. A risk for the development of hepatosplenic T-cell lymphoma
in patients treated with HUMIRA cannot be excluded.

All patients, and in particular patients with a medical history of
extensive immunosuppressant therapy or psoriasis patients with a history of
PUVA treatment, should be examined for the presence of non-melanoma skin
cancer prior to and during treatment with HUMIRA.

Rare reports of pancytopenia including aplastic anaemia have been
reported with TNF-blocking agents. Adverse events of the haematologic system,
including medically significant cytopenia have been infrequently reported
with HUMIRA.

Patients on HUMIRA may receive concurrent vaccinations, except for live
vaccines. Juvenile patients should be brought up to date with all
immunisations prior to initiating HUMIRA therapy, if possible.

In clinical studies with another TNF-antagonist, a higher rate of serious
congestive heart failure (CHF) related adverse events including worsening CHF
and new onset CHF have been reported. Cases of worsening CHF have also been
reported in patients receiving HUMIRA. Physicians should exercise caution
when using HUMIRA in patients with heart failure and monitor them carefully.

The combination of HUMIRA and anakinra or HUMIRA and abatacept is not
recommended.

Adverse Events at least possibly causally related to HUMIRA include very
common events (reported by >1/10 patients) respiratory tract infections
(including lower and upper respiratory tract infection, pneumonia, sinusitis,
pharyngitis, nasopharyngitis, pneumonia herpes viral), leucopaenia (including
neutropaenia, agranulocytosis), anaemia, lipids increased, headache,
abdominal pain, nausea and vomiting, liver enzymes elevated, rash (including
exfoliative rash), musculoskeletal pain, injection site reaction (including
injection site erythema); common events (reported by >1/100 but < 1/10
patients): systemic infections (including sepsis, candidiasis, influenza),
intestinal infections (including gastroenteritis viral), skin and soft tissue
infections (including paronychia, cellulitis, impetigo, necrotising
fasciitis, herpes zoster), ear infections, oral infections (including herpes
simplex, oral herpes, tooth infections), reproductive tract infections
(including vulvovaginal mycotic infection), urinary tract infections
(including pyelonephritis), fungal infections, benign neoplasm, skin cancer
excluding melanoma (including basal cell carcinoma, squamous cell carcinoma),
thrombocytopaenia, leucocytosis, hypersensitivity, allergies (including
seasonal allergy), hypokalaemia, uric acid increased, blood sodium abnormal,
hypocalcaemia, hyperglycemia, hypophosphotemia, blood potassium increased,
mood alterations (including depression), anxiety, insomnia, paraesthesias
(including hypoaesthesia), migraine, sciatica, visual impairment,
conjunctivitis, vertigo, tachycardia, hypertension, flushing, haematoma,
cough, asthma, dyspnoea, GI haemorrhage, dyspepsia, gastroesophageal reflux
disease, sicca syndrome, pruritus, urticaria, bruising (including purpura),
dermatitis (including eczema), onychoclasis, hyperhydrosis, muscle spasms
(including blood creatine phosphokinase increased), haematuria, renal
impairment, chest pain, oedema, coagulation and bleeding disorders (including
activated partial thromboplastin time prolonged), autoantibody test positive
(including double stranded DNA antibody), blood lactate dehydrogenase
increased, impaired healing.

Adverse drug reactions reported post-marketing include hepatosplenic
T-cell lymphoma, anaphylaxis, demyelinating disorders (including optic
neuritis, Guillain-Barre syndrome), cerebrovascular accident, intestinal
perforation, reactivation of hepatitis B, cutaneous vasculitis,
Stevens-Johnson syndrome, angioedema, new onset or worsening of psoriasis
(including palmoplantar pustular psoriasis), lupus-like syndrome, and
myocardial infarction.

About Abbott

Abbott is a global, broad-based health care company devoted to the
discovery, development, manufacture and marketing of pharmaceuticals and
medical products, including nutritionals, devices and diagnostics. The
company employs nearly 90,000 people and markets its products in more than
130 countries.

Abbott's news releases and other information are available on the
company's website at www.abbott.com.

Ana-Paula Barboza of Abbott, +1-847-938-2144